Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 7681 results

  1. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development [GID-TA11501] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

    Awaiting development [GID-TA11627] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493

    Awaiting development [GID-TA11639] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049

    Awaiting development [GID-TA11635] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046

    Awaiting development [GID-TA11632] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054

    Awaiting development [GID-TA11636] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Ublituximab for treating relapsing multiple sclerosis [ID6350]

    In development [GID-TA11268] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491

    Awaiting development [GID-TA11075] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 19 December 2024

    Technology appraisal guidance
    In development

  12. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  13. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407

    In development [GID-TA11498] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  15. PICO negative pressure wound dressings for closed surgical incisions (MTG43)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

    Medical technologies guidance
    Last updated
    6 August 2019
    View recommendations

    Sections for MTG43